A Study for PRO of CML in Real Word

Last updated: October 11, 2021
Sponsor: xuna
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT05092048
CML0922
  • Ages > 18
  • All Genders

Study Summary

Successful outcomes in CML require both prolonged adherence to oral TKI therapy by patients and careful monitoring of treatment responses by their physicians. Patient Reported Outcomes(PRO) assessment is important to facilitate decisions in the current treatment landscape of CML.

Study Design

Total Participants: 10000
Study Start date:
September 22, 2021
Estimated Completion Date:
October 01, 2022

Study Description

  1. Above 18 years of age.

  2. Patient with confirmed diagnosis of Philadelphia chromosome positive and/or BCR-ABL positive chronic myeloid leukemia (CML).

  3. Written informed consent.

  4. Patients enrolled in investigational drug-trials or other type of clinical trials are also eligible.

Connect with a study center

  • Department of Hematology, Nanfang Hospital, Southern Medical University,

    Guanzhou,
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.